Last reviewed · How we verify
AZD1152 part B
AZD1152 part B is a Aurora kinase inhibitor Small molecule drug developed by AstraZeneca. It is currently in Phase 1 development for Solid tumors.
AZD1152 is a selective Aurora B kinase inhibitor that disrupts mitotic progression and leads to cell cycle arrest and apoptosis in cancer cells.
AZD1152 is a selective Aurora B kinase inhibitor that disrupts mitotic progression and leads to cell cycle arrest and apoptosis in cancer cells. Used for Solid tumors.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Big-pharma sponsor
+3.0pp
AstraZeneca is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | AZD1152 part B |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | Aurora kinase inhibitor |
| Target | Aurora B |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 1 |
Mechanism of action
Aurora B kinase is a key regulator of mitosis, and its inhibition by AZD1152 leads to defects in chromosome segregation and cytokinesis, ultimately resulting in cell death.
Approved indications
- Solid tumors
Common side effects
- Neutropenia
- Thrombocytopenia
Key clinical trials
- Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticles as Monotherapy or in Combination in Acute Myeloid Leukemia Participants. (PHASE1)
- AZD1152 in Patients With Advanced Solid Malignancies (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AZD1152 part B CI brief — competitive landscape report
- AZD1152 part B updates RSS · CI watch RSS
- AstraZeneca portfolio CI
Frequently asked questions about AZD1152 part B
What is AZD1152 part B?
How does AZD1152 part B work?
What is AZD1152 part B used for?
Who makes AZD1152 part B?
What drug class is AZD1152 part B in?
What development phase is AZD1152 part B in?
What are the side effects of AZD1152 part B?
What does AZD1152 part B target?
Related
- Drug class: All Aurora kinase inhibitor drugs
- Target: All drugs targeting Aurora B
- Manufacturer: AstraZeneca — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Solid tumors
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing